Comment
Author: Admin | 2025-04-28
98.7 mm Hg, respectively. The mean lowest and highest IIEF-5 scores were 16 and 33, respectively. The total duration of the studies was 828 weeks (mean duration, 69 [range: 12 to 302] weeks), with the shortest duration of 12 weeks[18,19] and the longest duration being 302 weeks.[20] The baseline characteristics of the included studies are presented in Table 2 and Figure 1. Table 3 summarizes the main findings of the studies that were included in this review.Table 3:: Comparative interpretation of outcomes in included studiesStudy intervention All the included studies compared ARB interventions either as monotherapy and or in combination therapy with other antihypertensives such as atenolol, irbesartan, losartan, valsartan, telmisartan, and candesartan as monotherapy and or in combination therapy were investigated to determine their effect on erectile function. Felodipine, metoprolol, hydrochlorothiazide (HCTZ), and rosuvastatin belonging to other classes of antihypertensives were combined with the interventions in the included studies. At least one of the pre-specified outcomes was analyzed in patients with hypertension and ED in all included studies. Effect of ARBs on systolic blood pressure in patients with ED Ten included studies evaluated the effect of ARBs on systolic blood pressure in patients with hypertension and ED which showed comparable results.[6,18-26] A significant reduction in systolic blood pressure was observed in patients treated with irbesartan + HCTZ combination compared to irbesartan monotherapy (25 ± 14 vs. 22 ± 15 mm Hg; P [24] Nearly 46% of patients with sexual dysfunction achieved a reduction in systolic blood pressure (≤140 mm Hg) on treatment with losartan.[18] Similarly, valsartan treatment for six months significantly reduced systolic blood pressure from 158 ± 16 to 136 ± 9 mm Hg (P [23] Both atenolol and valsartan therapy significantly reduced systolic blood pressure after 16 weeks of treatment (−21/9 vs. −23/9 mm Hg) when compared to placebo (P [21] Similar rates of systolic blood pressure reduction were observed in patients on 16 weeks of treatment with valsartan monotherapy (−12%), valsartan + HCTZ combination (−11%), and conventional therapy (−11%).[22] The ONTARGET trial reported a greater reduction in systolic blood pressure with telmisartan + ramipril combination (−8.5
Add Comment